B8F.F - Biofrontera AG

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Biofrontera AG

Hemmelrather Weg 201
Leverkusen 51377


IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees110

Key Executives

NameTitlePayExercisedYear Born
Ms. Pilar de la Huerta MartinezCFO & Member of Exec. Board290.64kN/A1969
Mr. Ludwig M. LutterMember of the Exec. Board435.65kN/A1967
Mr. Alexander RichardsonHead of UK Sales TeamN/AN/AN/A
Dr. Matthias NaumannHead of Sales & Marketing - EuropeN/AN/AN/A
Dr. Montserrat Foguet Ph.D.Managing Director of Biofrontera UK Ltd.N/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin. It has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Corporate Governance

Biofrontera AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.